Tezepelumab Medicine 04 December 2025 Extended indication Tezepelumab monotherapy for treatment of Eosinophilic oesophagitis in adolescents, adults and elderly with previously documented standard of care treatment. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Tezepelumab Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Other chronic immune diseases Extended indication Tezepelumab monotherapy for treatment of Eosinophilic oesophagitis in adolescents, adults and elderly with previously documented standard of care treatment. Current proprietary name Already available biosimilars / generics Proprietary name Tezspire Manufacturer AstraZeneca Portfolio holder AstraZeneca Mechanism of action Immunosuppression Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date November 2026 Expected Registration October 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times every 4 weeks Dosage per administration 210mg tot 420mg References NCT05583227 (CROSSING) Additional remarks Tezepelumab 210mg om de 4 weken en tezepelumab 420mg om de 4 weken, subcutaan (SC) toegediend met behulp van een voorgevulde spuit met hulpstukken (APFS), versus placebo bij volwassen en adolescente deelnemers met EoE. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References mednet.nl Additional remarks Eosinofiele oesofagitis (EoE) is een chronische, progressieve inflammatoire aandoening, waarmee ongeveer 4.000 patiënten in Nederland gediagnosticeerd zijn. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use No Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks